Implications of melatonin therapy in irritable bowel syndrome: A systematic review

Current Pharmaceutical Design

Volumn 16, Issue 33, 2010, Pages 3646-3655

  Mozaffari, Shilan ^a   Rahimi, Roja ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Irritable bowel syndrome; Melatonin; Pharmaceutical management; Treatment

Indexed keywords

ANTIOXIDANT; CHOLECYSTOKININ; HYDROCHLORIC ACID; MELATONIN; NICOTINIC RECEPTOR; NITRIC OXIDE; SEROTONIN;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; IMMUNOMODULATION; IRRITABLE COLON; NONHUMAN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; ANIMAL; GASTROINTESTINAL TRACT; METABOLISM;

ANIMALS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MELATONIN;

EID: 79954536320     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210794079254     Document Type: Review

References (101)

1. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97(8): 1910-5.
2. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol 2009; 24: 1601-7.
3. Croghan A, Heitkemper MM. Recognizing and managing patients with irritable bowel syndrome. J Am Acad Nurse Pract 2005; 17: 51-9.
4. Foxx-Orenstein A. IBS-review and what's new. Med Gen Med 2006; 8: 20.
5. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
6. Ding Y, Lu B, Chen D, Meng L, Shen Y, Chen S. Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome. Proteomics 2010; 10: 2620-30.
7. O'Sullivan M, Clayton N, Moloney G, et al. Increased iNOS expression in irritable bowel syndrome (IBS) patients with stress related symptoms. Gastroenterology 2003; 124: 1642.
8. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable andinflammatory bowel diseases: Role of ATP. Recent Patents Endocr Metabol Immune Drug Discov 2009; 3: 69-75.
9. Zamani MJ, Sharifzadeh M, Rezaie A, Mashayekhi F, Abdollahi M. Effects of sildenafil on rat irritable bowel syndrome. Therapy 2005; 2: 237-42.
10. Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 2008; 17: 117-30.
11. Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 2006; 66: 1073-88.
12. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-53.
13. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15: 1548-53.
14. Fumi AL, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008; 42: 408-12.
15. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010; 6: 49-55.
16. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-80.
17. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884-901.
18. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-43.
19. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Alim Pharmacol Ther 2008; 27: 685-96.
20. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials Arch Med Sci 2008; 4: 71-6.
21. Shi J, Tong Y, Shen JG, Li HX. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008; 14: 454-62.
22. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-17.
23. Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5- methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 1960; 235: 1992-7.
24. Stefluj J, Horner M, Ghosh M, et al. Gene expression of the key enzymes in melatonin synthesis in extrapineal tissues in the rat. J Pineal Res 2001; 30: 243-7.
25. Bubenik GA. The effect of serotonin, N-acetylserotonin, and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res 1986; 3: 41-54.
26. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995; 16: 50-6.
27. Lee PP, Pang SF. Melatonin and its receptors in the gastrointestinal tract. Biol Signals 1993; 2: 181-93.
28. Luchcelli A, Santagostino-Barbone M, Tonini M. Investigation into the contractile response of melatonin in the guinea-pig isolated proximal colon: the role of 5-HT4 and melatonin receptors. Br J Pharmacol 1997; 121: 1775-81.
29. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
30. Nava F, Carta G. Melatonin reduces anxiety induced by lipopolysaccharide in the rat. Neurosci Lett 2001; 307: 57-60.
31. Papp M, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006; 17: 9-18.
32. Papp M, Gruca P, Boyer PA, Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28: 694-703.
33. Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol 1993; 237: 231-6.
34. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000; 25: 48-52.
35. Malhotra S, Sawhney G, Pandhi P. The therapeutic potential of melatonin: a review of the science. MedGenMed 2004; 6: 46.
36. Klepac N, Rudes Z, Klepac R. Effects of melatonin on plasma oxidative stress in rats with streptozotocin induced diabetes. Biomed Pharmacother 2006; 60: 32-5.
37. Baydas G, Canatan H, Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocininduced diabetes mellitus. J Pineal Res 2002; 32: 225-30.
38. Aksoy N, Vural H, Sabuncu T, Aksoy S. Effects of melatonin on oxidative-antioxidative status of tissues in streptozotocin-induced diabetic rats. Cell Biochem Funct 2003; 21: 121-5.
39. Montilla PL, Vargas JF, Túnez IF, Muñoz de Agueda MC, Valdelvira ME, Cabrera ES. Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin. J Pineal Res 1998; 25: 94-100.
40. Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42: 276-85.
41. Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17: 1683-90.
42. Mayo JC, Sainz RM, Tan DX, Antolín I, Rodríguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005; 27: 169-78.
43. Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1, 2-dimethylhydrazine in rats. Carcinogenesis 1997; 18: 1549-53.
44. Lissoni P, Barni S, Cattaneo G, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology 1991; 48: 448-50.
45. Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30: 1-12.
46. Mei Q, Yu JP, Xu JM, Wei W, Xiang L, Yue L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-6.
47. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran- induced colitis in mice. J Pineal Res 1995; 19: 31-9.
48. Bubenik GA, Ayles HL, Friendship RM, Brown GM, Ball RO. Relationship between melatonin levels in plasma and gastrointestinal tissues and the incidence and severity of gastric ulcers in pigs. J Pineal Res 1998; 24: 62-6.
49. Bandyopadhyay D, Biswas K, Bandyopadhyay U, Reiter RJ, Banerjee RK. Melatonin protects against stress-induced gastric lesions by scavenging the hydroxyl radical. J Pineal Res 2000; 29: 143-51.
50. Konturek SJ, Konturek PC, Brzozowski T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J Physiol Pharmacol 2006; 57: 51-66.
51. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Alim Pharmacol Ther 2005; 22: 927-34.
52. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-7.
53. Weissbluth L, Weissbluth M. Infant colic: the effect of serotonin and melatonin circadian rhythms on the intestinal smooth muscle. Med Hypotheses 1992; 39: 164-7.
54. Weissbluth M, Weissbluth L. Colic, sleep inertia, melatonin and circannual rhythms. Med Hypotheses 1992; 38: 224-8.
55. Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia 1993; 49: 665-70.
56. Raikhlin NT, Kvetnoǐ IM. 5-Methoxy-N-acetyltryptamine (melatonin) in enterochromaffin cells. Tsitologiia 1975; 17: 1047-50.
57. Lepage O, Larson ET, Mayer I, Winberg S. Tryptophan affects both gastrointestinal melatonin production and interrenal activity in stressed and nonstressed rainbow trout. J Pineal Res 2005; 38:264-71.
58. Huether G, Poeggeler B, Reimer A, George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51: 945-53.
59. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-48.
60. Huether G. Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin. Ann N Y Acad Sci 1994; 719: 146-58.
61. Messner M, Huether G, Lorf T, Ramadori G, Schwörer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-51.
62. Bubenik GA, Pang SF, Hacker RR, Smith PS. Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J Pineal Res 1996; 21: 251-6.
63. Bubenik GA, Ball RO, Pang SF. The effect of food deprivation on brain and gastrointestinal tissue levels of tryptophan, serotonin, 5- hydroxyindoleacetic acid, and melatonin. J Pineal Res 1992; 12: 7-16.
64. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept 2001; 10: 350-66.
65. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59: 33-51.
66. Bubenik GA, Pang SF. The role of serotonin and melatonin in gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonin-melatonin feedback. J Pineal Res 1994; 16: 91-9.
67. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Bandyopadhyay D. Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J Physiol Pharmacol 2003; 54: 113-25.
68. Bubenik GA, Blask DE, Brown GM, et al. Prospects of the clinical utilization of melatonin. Biol Signals Recept 1998; 7: 195-219.
69. Konturek PC, Konturek SJ, Majka J, Zembala M, Hahn EG. Melatonin affords protection against gastric lesions induced by ischemia- reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol 1997; 322: 73-7.
70. Klupińska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol 2007; 41: 270-4.
71. Klupińska G, Wiśniewska-Jarosińska M, Harasiuk A, et al. Nocturnal secretion of melatonin in patients with upper digestive tract disorders. J Physiol Pharmacol 2006; 57: 41-50.
72. Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern Ther Health Med 2008; 14: 54-8.
73. Storr M, Koppitz P, Sibaev A, et al. Melatonin reduces nonadrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. J Pineal Res 2002; 33: 101-8.
74. Bubenik GA, Hacker RR, Brown GM, Bartos L. Melatonin concentrations in the luminal fluid, mucosa, and muscularis of the bovine and porcine gastrointestinal tract. J Pineal Res 1999; 26: 56-63.
75. Maestroni GJ. The immunoneuroendocrine role of melatonin. J Pineal Res 1993; 14: 1-10.
76. Fraschini F, Demartini G, Esposti D, Scaglione F. Melatonin involvement in immunity and cancer. Biol Signals Recept 1998; 7: 61-72.
77. Sasaki M, Jordan P, Joh T, et al. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol 2002; 2: 9.
78. Brzozowski T, Konturek PC, Konturek SJ, et al. The role of melatonin and L-tryptophan in prevention of acute gastric lesions induced by stress, ethanol, ischemia, and aspirin. J Pineal Res 1997; 23: 79-89.
79. Konturek PC, Konturek SJ, Brzozowski T, et al. Gastroprotective activity of melatonin and its precursor, L-tryptophan, against stressinduced and ischaemia-induced lesions is mediated by scavenge of oxygen radicals. Scand J Gastroenterol 1997; 32: 433-8.
80. Barajas-López C, Peres AL, Espinosa-Luna R, Reyes-Vázquez C, Prieto-Gómez B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus. Eur J Pharmacol 1996; 312: 319-25.
81. Harlow HJ, Weekley BL. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986; 3: 277-84.
82. Quastel MR, Rahamimoff R. Effect of melatonin on spontaneous contractions and response to 5-hydroxytryptamine of rat isolated duodenum. Br J Pharmacol Chemother 1965; 24: 455-61.
83. Bonouali-Pellissier S. Melatonin is involved in cholecystokinininduced changes of ileal motility in rats. J Pineal Res 1994; 17: 79-85.
84. Bubenik GA, Dhanvantari S. Influence of serotonin and melatonin on some parameters of gastrointestinal activity. J Pineal Res 1989; 7: 333-44.
85. Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009; 54: 1087-93.
86. Kasimay O, Cakir B, Devseren E, Yegen BC. Exogenous melatonin delays gastric emptying rate in rats: role of CCK2 and 5-HT3 receptors. J Physiol Pharmacol 2005; 56: 543-53.
87. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 2007; 58: 97-103.
88. Drago F, Macauda S, Salehi S. Small doses of melatonin increase intestinal motility in rats. Dig Dis Sci 2002; 47: 1969-74.
89. Storr M, Schusdziarra V, Allescher HD. Inhibition of small conductance K+ channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can J Physiol Pharmacol 2000; 78: 799-806.
90. Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity. III. Melatonin antagonizes the immunosuppressive effect of acute stress via an opiatergic mechanism. Immunology 1988; 63: 465-9.
91. Reiter RJ, Melchiorri D, Sewerynek E, et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995; 18: 1-11.
92. De La Lastra CA, Cabeza J, Motilva V, Martin MJ. Melatonin protects against gastric ischemia-reperfusion injury in rats. J Pineal Res 1997; 23: 47-52.
93. Roberts-Thomson IC, Knight RE, Kennaway DJ, Pannall PR. Circadian rhythms in patients with abdominal pain syndromes. Aust N Z J Med 1988; 18: 569-74.
94. Komarov FI, Raǐkhlin NT, Rapoport SI, Malinovskaia NK, Voznesenskaia LA, Rumiantseva AI. Irritated bowel syndrome: clinicomorphological aspects of treatment with melaxen. Klin Med (Mosk) 2006; 84: 30-6.
95. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 1499-506.
96. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32.
97. Stepień A, Moskwa-Fortuna A, Wisniewska-Jarosińska M, Harasiuk A, Chojnacki J. Melatonin secretion and metabolism in patients with irritable bowel syndrome. Pol Merkur Lekarski 2009; 26: 440-3.
98. Radwan P, Skrzydlo-Radomanska B, Radwan-Kwiatek K, Burak- Czapiuk B, Strzemecka J. Is melatonin involved in the irritable bowel syndrome? J Physiol Pharmacol 2009; 60: 67-70.
99. Elsenbruch S. Melatonin: a novel treatment for IBS? Gut 2005; 54: 1353-4.
100. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-97.
101. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-95.